Back to today’s briefing

Story perspectives

Valneva's IXCHIQ Vaccine Could Prevent 34,200 Chikungunya Cases

5/5/2025

43 9

Summary

Story summary

Valneva SE's IXCHIQ® chikungunya vaccine has emerged as a powerful defense against the virus impacting 100 countries. A groundbreaking study in Nature Medicine reveals that this vaccine could have averted 34,200 cases during a recent outbreak in Paraguay. Now available in the U.S., IXCHIQ is officially endorsed by the CDC, offering hope for better prevention.

1 of 1

Story summary

Valneva SE's IXCHIQ® chikungunya vaccine has emerged as a powerful defense against the virus impacting 100 countries. A groundbreaking study in Nature Medicine reveals that this vaccine could have averted 34,200 cases during a recent outbreak in Paraguay. Now available in the U.S., IXCHIQ is officially endorsed by the CDC, offering hope for better prevention.